We also investigated whether squamocin could degrade other EZH2's non‐catalytic binding partners, such as p300[30] and RelA.[31] The results indicated that the accumulation of p300, but not RelA (p65), was reduced in two HNSCC cells treated with squamocin (Figure 4H). This evidence concerns the gene EP300 and head and neck squamous cell carcinoma.